Immunome, Inc. (IMNM)
IMNM moved a median of -0.08% 30 minutes after news, and -0.66% by the close. How IMNM actually reacts to news — the realized, point-in-time move the market made, measured across 346 labeled events over the last three years with zero look-ahead.
IMNM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 41% | 344 |
| 30-min | -0.08% | 47% | 345 |
| 60-min | -0.38% | 44% | 346 |
| to close | -0.66% | 48% | 345 |
| Middle 50% of IMNM reactions | -1.65% to +1.44% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 346 |
Half of all Immunome, Inc. news events land between -1.65% and +1.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMNM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 42 | -0.55% | 43% | -1.03% |
| Rating reiterations | 54 | +0.05% | 52% | +0.68% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how IMNM ranks against every other measured name →
That’s how IMNM usually reacts — get an email when it moves on news →Email me when IMNM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMNM's baseline. Nothing else.
Recent IMNM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.90% | +0.82% | |
| Form 8-K Immunome Inc. For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +1.88% | +1.83% | |
| Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors | Press release | Business Wire | -0.70% | -2.89% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.23% | -1.17% | |
| Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | +1.65% | -0.83% | |
| Form 10-Q Immunome Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.95% | +9.38% | |
| Form 8-K Immunome Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +1.95% | +9.38% | |
| Form S-8 Immunome Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.95% | +9.38% | |
| Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | +1.95% | +9.38% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.38% | -4.43% | |
| Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors | Press release | Business Wire | +0.67% | -1.07% | |
| Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors | Press release | Business Wire | +0.85% | -0.66% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.85% | -0.66% | |
| Form 8-K Immunome Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -3.01% | |
| Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors | Press release | Business Wire | +1.09% | +1.55% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.05% | -5.01% | |
| Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting | Press release | Business Wire | -4.52% | -2.21% | |
| Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | -0.82% | +0.64% | |
| Form 10-Q Immunome Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.59% | -5.09% | |
| Form 8-K Immunome Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -2.59% | -5.09% | |
| Immunome Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -2.59% | -5.09% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.20% | -0.21% | |
| Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors | Press release | Business Wire | -1.16% | -1.54% | |
| Form ARS Immunome Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.84% | +0.30% | |
| Form DEF 14A Immunome Inc. For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | +1.84% | +0.30% | |
| Form DEFA14A Immunome Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.84% | +0.30% | |
| Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting | Press release | Business Wire | +0.17% | -1.85% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.90% | -0.69% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.88% | +4.26% | |
| Form 10-K Immunome Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.41% | +2.36% | |
| Form 8-K Immunome Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | +2.36% | |
| Form S-8 Immunome Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.41% | +2.36% | |
| Immunome Reports Full Year 2025 Financial Results and Provides Business Update | Press release | Business Wire | -1.41% | +2.36% | |
| Immunome to Present at Upcoming Investor Conferences | Press release | Business Wire | +1.85% | +0.97% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +4.67% | +1.10% | |
| Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | Business Wire | +2.33% | -2.19% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.60% | +0.72% | |
| Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.10% | +0.51% | |
| Form 8-K Immunome Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +0.84% | -1.04% | |
| Immunome Announces Pricing of Public Offering of Common Stock | Press release | Business Wire | -0.60% | -8.51% | |
| Form 8-K Immunome Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | -3.89% | -1.22% | |
| Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors | Press release | Business Wire | -3.89% | -1.22% | |
| Immunome Announces Proposed Public Offering of Common Stock | Press release | Business Wire | -0.09% | +2.62% | |
| Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors | Press release | Business Wire | -3.89% | -1.22% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.45% | -1.59% | |
| Immunome to Present at Upcoming Investor Conferences | Press release | Business Wire | -1.09% | -2.97% | |
| Form 10-Q Immunome Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.75% | -1.36% | |
| Form 8-K Immunome Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -1.36% | |
| Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | Business Wire | -1.75% | -1.36% | |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -2.65% | -0.78% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMNM section they belong to.
Where else IMNM is measured.
IMNM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immunome, Inc.'s median reaction calculated?
Every labeled IMNM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 346 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of IMNM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMNM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.